This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.

The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.

The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.

The present disclosure provides at least one skin supplement composition that has been shown to be advantageous for healthy skin, preferably comprised of hydrolyzed collagen, glucosamine sulfate, biotin, vitamin A palmitate, vitamin E, alpha lipoic acid, coenzyme Q.sub.10, pine bark extract, L-selenomethionone and niacinamide. An advantageous nootropic composition is also disclosed preferably comprised of ascorbic acid, taurine, elemental magnesium, glycinate, L-theanine, L-tyrosine, pine bark extract, N-acetyl-L-carnitine, DL-choline bitartrate, maca root, glucosinolates, P5P (pyridoxal-5-phosphate) and alpha ketoglutaric acid. A method to provide a specifically tailored supplement is also disclosed, preferably of collecting dry blood spots, analyzing the dry blood spots with tandem mass spectrometry, determining an amino acid kinetic pattern based on the analysis, and generating the specifically tailor supplement based on the pattern.

The present disclosure provides at least one skin supplement composition that has been shown to be advantageous for healthy skin, preferably comprised of hydrolyzed collagen, glucosamine sulfate, biotin, vitamin A palmitate, vitamin E, alpha lipoic acid, coenzyme Q.sub.10, pine bark extract, L-selenomethionone and niacinamide. An advantageous nootropic composition is also disclosed preferably comprised of ascorbic acid, taurine, elemental magnesium, glycinate, L-theanine, L-tyrosine, pine bark extract, N-acetyl-L-carnitine, DL-choline bitartrate, maca root, glucosinolates, P5P (pyridoxal-5-phosphate) and alpha ketoglutaric acid. A method to provide a specifically tailored supplement is also disclosed, preferably of collecting dry blood spots, analyzing the dry blood spots with tandem mass spectrometry, determining an amino acid kinetic pattern based on the analysis, and generating the specifically tailor supplement based on the pattern.

The present invention concerns a beverage having water and a concentration range of about 0.001 grams per liter to 8.44 grams per liter of collagen, wherein the collagen is hydrolyzed. The collagen concentration range may be between 1 milligram per liter to about 8440 milligram per liter or 1 parts per million to about 8440 parts per million. The hydrolyzed collagen has collagen peptides. The collagen peptides are produced through hydrolysis of a plurality of collagen sources. The plurality of collagen sources are derived from at least one of animal raw materials, animals raised in non-organic or organic farms, animals from various animal species and various parts of the animal carcass. The water may be comprised of at least one of tap water, spring or mineral water, and iceberg or glacier water.

An object of the present invention is to provide a trophic factor releasing agent and an inflammatory disease treating agent in which an amount of trophic factors released from cells in a cell transplantation treatment or the like is increased. According to the present invention, there is provided a trophic factor releasing agent including a cell structure that includes biocompatible polymer blocks and cells and in which a plurality of the biocompatible polymer blocks are disposed in gaps between a plurality of the cells, in which a size of one of the biocompatible polymer blocks is 20 m to 200 m, and trophic factors are released from the cells.

In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.

The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

A tissue repair and wound healing composition with low molecular weight hydrolyzed collagen is provided. The wound healing composition with low molecular weight hydrolyzed collagen is a medicinal composition for facilitating the growth, protection and healing of tissues and cells in animals and humans. The main ingredient of the formulated composition is hydrolyzed collagen having a molecular weight of less than 499 Da, which can be combined with polysulfated glycosaminoglycans, hyaluronic acid or salts thereof, or a glucosamine salt, and mixtures thereof. The composition may include hydrolyzed collagen from multiple sources, such as bovine sourced hydrolyzed collagen or marine sourced hydrolyzed collagen and may further include hydrolyzed whey.